Update in cystic fibrosis 2011

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 9, 2012, Pages 933-936

  Ratjen, Felix ^a   McColley, Susanna A ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ARGINASE; CEFTAZIDIME; CIPROFLOXACIN; INTERLEUKIN 17; IVACAFTOR; LEVOFLOXACIN; LUMACAFTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; BURKHOLDERIA CEPACIA; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; LUNG FUNCTION; LUNG INFECTION; LUNG LAVAGE; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; SHORT SURVEY; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; RESPIRATORY SYSTEM;

EID: 84860642711     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201202-0306UP     Document Type: Short Survey

References (32)

1. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183:1463-1471.
2. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-291.
3. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-856.
4. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328. (Pubitemid 29523443)
5. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, et al.; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306:163-171.
6. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA, Winstanley C. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am J Respir Crit Care Med 2011;183:1674-1679.
7. Workentine M, Surrette MG. Complex pseudomonas population structure in cystic fibrosis airway infections. Am J Respir Crit Care Med 2011;183:1581-1583.
8. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbacterial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011;24:29-70.
9. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, Tom S, Tullis E, Ratjen F. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011;183:635-640.
10. Colin AA, Rabin HR. Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent? Am J Respir Crit Care Med 2011;183:564-566.
11. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161.
12. Zlosnik JEA, Costa PS, Brant R, Mori PYB, Hird TJ, Fraenkel MC, Wilcox PG, Davidson GAF, Speert DP. Mucoid and nonmucoid Burkolderia cepacia complex bacteria in cystic fibrosis infections. Am J Respir Crit Care Med 2011;183:67-72.
13. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006;174:208-212. (Pubitemid 44015394)
14. Grasemann H, Schwiertz R, Matthiesen S, Racke K, Ratjen F. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005;172:1523-1528. (Pubitemid 43076540)
15. Grasemann H, Al-Saleh S, Scott JA, Shehnaz D, Mehl A, Amin R, Rafii M, Pencharz P, Belik J, Ratjen F. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183:1363-1368.
16. Marozkina NV, Gaston B. Nitrogen balance in the ecosystem of the cystic fibrosis lung. Am J Respir Crit Care Med 2011;183:1290-1293.
17. Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, Massie J, Hall GL, Sly P, Stick S, et al.; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75-81.
18. Tan H, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The th17 pathway in cystic fibrosis lung disease. Am J Respir Crit CareMed 2011; 184:252-258.
19. Dubin PJ, Tolls JK. IL-17 in cystic fibrosis: more than just th17 cells. Am J Respir Crit Care Med 2011;184:155-157.
20. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011;183:1517-1523.
21. Shoseyov D, Cohen-Cymberknoh M, Kerem E. Could you please pass the salt? Am J Respir Crit Care Med 2011;183:1444-1446.
22. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2001;176:957-969.
23. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS. Conrad DJ; Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-1516.
24. Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW. Phase II randomized safety and efficacy trial of denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007;17:362-369. (Pubitemid 47267470)
25. Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA. Ramsey BW; TIGER-1 Investigator Study Group. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183:627-634.
26. Stick SM, Sly PD. Exciting new clinical trials in cystic fibrosis: infants need not apply. Am J Respir Crit Care Med 2011;183:1577-1578.
27. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
28. Sanders DB, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. Am J Respir Crit Care Med 2011;184:816-821.
29. Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A, et al.; The London Cystic Fibrosis Collaboration. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011;183:752-758.
30. Daines C, Morgan W. The importance of imaging in cystic fibrosis. Am J Respir Crit Care Med 2011;184:751-752.
31. Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH. Risk factors for chronic kidney disease in adults with cystic fibrosis. Am J Respir Crit Care Med 2011;184:1147-1152.
32. Schechter MS, Stecenko AA. Chronic kidney disease: a new morbidity of cystic fibrosis or an old morbidity of diabetes mellitus? Am J Respir Crit Care Med 2011;184:1101-1102.